Disparities in bone density measurement history and osteoporosis medication utilisation in Swiss women: results from the Swiss Health Survey 2007

BMC Musculoskeletal Disorders

Marcel Zwahlen¹  Rita Born¹ 

[1] Institute of Social and Preventive Medicine, Bern University, Bern, Switzerland

关键词: Health survey;    Socioeconomic;    Sociodemographic;    Medication;    Osteoporosis;    Bone density measurement;   

Others  :  1134250
DOI  :  10.1186/1471-2474-14-10

 received in 2012-03-12, accepted in 2012-12-13,  发布年份 2013

【 摘 要 】

Background

Although factors associated with the utilisation of bone density measurement (BDM) and osteoporosis treatment have been regularly assessed in the US and Canada, they have not been effectively analysed in European countries. This study assessed factors associated with the utilisation of BDM and osteoporosis medication (OM) in Switzerland.

Methods

The Swiss Health Survey 2007 data included self-reported information on BDM and OM for women aged 40 years and older who were living in private households. Multivariable logistic regression analysis was used to identify sociodemographic, socioeconomic, healthcare-related and osteoporosis risk factors associated with BDM and OM utilisation.

Results

The lifetime prevalence of BDM was 25.6% (95% CI: 24.3-26.9%) for women aged 40 years and older. BDM utilisation was associated with most sociodemographic factors, all the socioeconomic and healthcare-related factors, and with major osteoporosis risk factors analysed. The prevalence of current OM was 7.8% (95% CI: 7.0-8.6%) and it was associated with some sociodemographic and most healthcare-related factors but only with one socioeconomic factor.

Conclusions

In Swiss women, ever having had a BDM and current OM were low and utilisation disparities exist according to sociodemographic, socioeconomic and healthcare-related factors. This might foster further health inequalities. The reasons for these findings should be addressed in further studies of the elderly women, including those living in institutions.

【 授权许可】

   
2013 Born and Zwahlen; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lippuner K, Johansson H, Kanis JA, Rizzoli R: Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 2009, 20(7):1131-1140.
• [2]Federal Office of Public Health: Osteoporose und Stürze im Alter. 2004, 1-84.
• [3]Schwenkglenks M, Lippuner K, Häuselmann HJ, Szucs TD: A model of osteoporosis impact in Switzerland 2000–2020. Osteoporos Int 2005, 16(6):659-671.
• [4]Kanis JA, Burlet N, Cooper C, Delmas P: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19(4):399-428.
• [5]Siris ES, Baim S, Nattiv A: Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men. Postgrad Med 2010, 122(1):82-90.
• [6]World Health Organisation: FRAX Fracture Risk Assessment: Calculation Tool for Switzerland. http://www.shef.ac.uk/FRAX/tool.jsp?country=15 webcite
• [7]Schwenkglenks M, Lippuner K: Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 2007, 18(11):1481-1491.
• [8]Lippuner K, Popp A, Szucs T, Schwenkglenks M: Kosteneffektivität einer Osteoporose- Behandlung nach systematischem Bevölkerungsscreening in der Schweiz: Auswirkungen der Preisreduktion des Alendronat-Originalpräparates. Pharmaco Economics 2008, 6(1):19-28.
• [9]Swiss Union Against Osteoporosis: Empfehlung zur Osteoporose Diagnostik, Prävention, Behandlung. 2003, 1-23.
• [10]Federal Department of Home Affairs: SR 832.112.31 Krankenpflege- Leistungsverordnung KLV Art.1: Pflichtleistungen der Krankenkassen, Anhang 1. 2001.
• [11]Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002, 167(10 Suppl):S1-S34.
• [12]U. S. Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002, 137(6):526-528.
• [13]U. S. Preventive Services Task Force: Screening for osteoporosis: U.S. Preventive services task force recommendation statement. Ann Intern Med 2011, 154(5):356-364.
• [14]Demeter S, Leslie WD, Lix L, MacWilliam L, Finlayson GS, Reed M: The effect of socioeconomic status on bone density testing in a public health-care system. Osteoporos Int 2007, 18(2):153-158.
• [15]Neuner JM, Zhang X, Sparapani R, Laud PW, Nattinger AB: Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med 2007, 22(9):1239-1245.
• [16]Nayak S, Roberts MS, Greenspan SL: Factors associated with diagnosis and treatment of osteoporosis in older adults. Osteoporos Int 2009, 20(11):1963-1967.
• [17]Vanasse A, Dagenais P, Niyonsenga T, Grégoire JP, Courteau J, Hemiari A: Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 2005, 6:33. BioMed Central Full Text
• [18]Brennan RM, Wactawski-Wende J, Crespo CJ, Dmochowski J: Factors associated with treatment initiation after osteoporosis screening. Am J Epidemiol 2004, 160(5):475-483.
• [19]Federal Office of Public Health: List of pharmaceutical specialities LS. 2011.
• [20]Bisig B, Gutzwiller F: Gesundheitswesen Schweiz: gibt es Unter- oder Überversorgung? Die Bedeutung von Sozialschicht, Wohnregion, Nationalität, Geschlecht und Versicherungstatus. NFP45 Rüegger Verlag 2004, 1:1-247.
• [21]Swiss Federal Statistical Office: Rapport de méthodes - Enquête suisse sur la santé 2007. 2010, 1-68.
• [22]Swiss Federal Statistical Office: Schweizerische Gesundheitsbefragung 2007 in Kürze: Konzept, Methode, Durchführung. 2008, 1-9.
• [23]Swiss Federal Statistical Office: Schweizerische Gesundheitsbefragung 2007: Telefonischer und schriftlicher Fragebogen. 2010, 1-126.
• [24]Swiss Federal Statistical Office: Schweizerische Gesundheitsbefragung 2007: Die Indizes. 2010, 1-89.
• [25]Federal Council: SR 431.012.1 Verordnung vom 30. Juni 1993 über die Durchführung von statistischen Erhebungen des Bundes (Statistikerhebungsverordnung). 1993.
• [26]Johnell O, Kanis JA: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17(12):1726-1733.
• [27]Schmidlin K: Wie häufig und wie unterschiedlich werden Krebsvorsorgeuntersuchungen von der Schweizerischen Bevölkerung verwendet: Eine Auswertung der Schweizerischen Gesundheitsbefragung. CDSP Saphir 2002, 2006:1-57.
• [28]Fontana M, Bischoff A: Uptake of breast cancer screening measures among immigrant and Swiss women in Switzerland. Swiss Med Wkly 2008, 138(49–50):752-758.
• [29]Wanner P, Raymond L, Bouchardy C: Geographical disparities in self-reported use of mammography and breast self-examination according to the Swiss health survey. Ann Oncol 2001, 12(4):573-574.
• [30]Keller B, Stutz EZ, Tibblin M, Ackermann-Liebrich U, Faisst K, Probst-Hensch N: Screening mammographies in Switzerland: what makes female and male physicians prescribe them? Swiss Med Wkly 2001, 131(21–2):311-319.
• [31]Register of DEXA centres in Switzerland. http://www.dexa.ch/ webcite
• [32]Wang MC, Dixon LB: Socioeconomic influences on bone health in postmenopausal women: findings from NHANES III, 1988–1994. Osteoporos Int 2006, 17(1):91-98.
• [33]Mulherin DM, Smith JA, Price T: Is patient anxiety about osteoporosis sufficient indication for measuring bone mineral density? Clin Exp Rheumatol 2000, 18(6):789.
• [34]Swiss Union Against Osteoporosis: Empfehlung zur Osteoporose Prävention Diagnostik Behandlung. 2010, 1-16.
• [35]Allemann S, Saner C, Zwahlen M, Christ ER, Diem P, Stettler C: Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. Swiss Med Wkly 2009, 139(39–40):576-583.
• [36]Nayak S, Roberts MS, Greenspan SL: Factors associated with osteoporosis screening and recommendations for osteoporosis screening in older adults. J Gen Intern Med 2009, 24(5):585-591.
• [37]Holroyd C, Cooper C, Dennison E: Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008, 22(5):671-685.
• [38]Suhm N, Lamy O, Lippuner K, OsteoCare study group: Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 2008, 138(45–6):674-683.
• [39]Schürch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP: A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996, 11(12):1935-1942.